AMENDMENT #1 TO SHARED SPACE ARRANGEMENTShared Space Arrangement • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment #1 To Shared Space Arrangement (this “Amendment”) is made effective as of July 1, 2024, by and between OMEGA THERAPEUTICS, INC., a Delaware corporation (“Licensor” or “Tenant”), having an address of 140 First Street, Ste 501, Cambridge, MA 02141, and Metaphore Biotechnologies, Inc., (“Licensee” or “Space Occupant”), having an address of 140 First Street, Ste 502, Cambridge, MA 02141.
THIRD AMENDMENT TO LEASELease • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is dated as of July 31, 2024 (the “Third Amendment Effective Date”), by and between ARE-MA REGION NO. 94, LLC, a Delaware limited liability company (“Landlord”), and OMEGA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SHARED SPACE ARRANGEMENTShared Space Arrangement • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This shared space arrangement (this “Shared Space Arrangement”) is made and entered into effective as of the 1st day of August, 2024 (the “Effective Date”) by and between Omega Therapeutics, Inc., a Delaware corporation (“Licensor” or “Tenant”) with an address of 140 First Street, Ste 501, Cambridge, Massachusetts 02141, and Flagship Labs 97, Inc., a Delaware corporation (“Licensee” or “Space Occupant”), with an address of 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142.
SECOND AMENDMENT TO LEASETo Lease • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is dated as of June 24_, 2024 (the “Second Amendment Effective Date”), by and between ARE-MA REGION NO. 94, LLC, a Delaware limited liability company (“Landlord”), and OMEGA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
Amended and Restated Employment AgreementAmended and Restated Employment Agreement • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”), is entered into on May 28, 2024, by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Barbara Chan (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”) and shall become effective on May 31, 2024 (the “Effective Date”), subject to Executive’s continued employment with the Company through the Effective Date.
Separation Agreement and ReleaseSeparation Agreement and Release • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Separation Agreement and Release (“Agreement”) is made by and between Yan Moore (“Executive”) and Omega Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below).
Separation Agreement and ReleaseSeparation Agreement and Release • August 6th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Separation Agreement and Release (“Agreement”) is made by and between Joshua Reed (“Executive”) and Omega Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below).
